132 related articles for article (PubMed ID: 18771350)
1. Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer.
Sakai T; Yamashita Y; Maekawa T; Mikami K; Hoshino S; Shirakusa T
Cancer Biother Radiopharm; 2008 Aug; 23(4):461-7. PubMed ID: 18771350
[TBL] [Abstract][Full Text] [Related]
2. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).
Mitomi T; Tsuchiya S; Iijima N; Aso K; Suzuki K; Nishiyama K; Amano T; Takahashi T; Murayama N; Oka H
Dis Colon Rectum; 1992 Feb; 35(2):123-30. PubMed ID: 1735313
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial.
Ohwada S; Kawate S; Ikeya T; Yokomori T; Kusaba T; Roppongi T; Takahashi T; Nakamura S; Kawashima Y; Nakajima T; Morishita Y;
Dis Colon Rectum; 2003 Aug; 46(8):1060-8. PubMed ID: 12907900
[TBL] [Abstract][Full Text] [Related]
4. Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).
Mori T; Ohue M; Takii Y; Hashizume T; Kato T; Kotake K; Sato T; Tango T
Oncol Rep; 2013 Feb; 29(2):437-44. PubMed ID: 23232805
[TBL] [Abstract][Full Text] [Related]
5. [Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum].
Mitomi T; Tsuchiya S; Iijima N; Aso K; Suzuki K; Nishiyama K; Amano T; Takahashi T; Murayama N; Oka H
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2241-9. PubMed ID: 2500070
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer.
Yoshitani S; Takashima S
Cancer Biother Radiopharm; 2009 Feb; 24(1):35-40. PubMed ID: 19243246
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
Koda K; Miyazaki M; Sarashina H; Suwa T; Saito N; Suzuki M; Ogawa K; Watanabe S; Kodaira S; Nakazato H
Int J Oncol; 2003 Jul; 23(1):165-72. PubMed ID: 12792790
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of immunochemotherapy with PSK, a protein-bound polysaccharide, in colorectal cancer and changes of tumor marker.
Kudo S; Tanaka J; Kashida H; Tamegai Y; Endo S; Yamano HO
Oncol Rep; 2002; 9(3):635-8. PubMed ID: 11956642
[TBL] [Abstract][Full Text] [Related]
9. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor.
Munemoto Y; Iida Y; Ohata K; Saito H; Fujisawa K; Kasahara Y; Mitsui T; Asada Y; Miura S
Oncol Rep; 2004 Mar; 11(3):623-35. PubMed ID: 14767513
[TBL] [Abstract][Full Text] [Related]
10. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU.
Takahashi Y; Mai M; Nakazato H
Anticancer Res; 2005; 25(2B):1377-84. PubMed ID: 15865094
[TBL] [Abstract][Full Text] [Related]
11. [Usefulness in predicting parameters for the selection of responders who received immunochemotherapy with PSK in patients with colorectal cancer].
Yoshino S; Hazama S; Shimizu R; Fukuda S; Kudoh A; Mizuta E; Ogura Y; Sano A; Oka M
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1568-70. PubMed ID: 16315871
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer.
Alliot C
Br J Cancer; 2004 Sep; 91(6):1220-1; author reply 1221-3. PubMed ID: 15305190
[No Abstract] [Full Text] [Related]
13. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.
Ito K; Nakazato H; Koike A; Takagi H; Saji S; Baba S; Mai M; Sakamoto J; Ohashi Y;
Int J Colorectal Dis; 2004 Mar; 19(2):157-64. PubMed ID: 13680286
[TBL] [Abstract][Full Text] [Related]
14. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.
Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
Anticancer Res; 1997; 17(4A):2815-8. PubMed ID: 9252721
[TBL] [Abstract][Full Text] [Related]
15. Protein-bound polysaccharide K partially prevents apoptosis of circulating T cells induced by anti-cancer drug S-1 in patients with gastric cancer.
Kono K; Kawaguchi Y; Mizukami Y; Mimura K; Sugai H; Akaike H; Fujii H
Oncology; 2008; 74(3-4):143-9. PubMed ID: 18708731
[TBL] [Abstract][Full Text] [Related]
16. [Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer--7-year survival--Cooperative Study Group for Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group].
Ichihashi H; Kondo T; Nakazato H
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2758-66. PubMed ID: 3307635
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur.
Watanabe M; Nishida O; Kunii Y; Kodaira S; Takahashi T; Tominaga T; Hojyo K; Kato T; Niimoto M; Kunitomo K; Isomoto H; Ohashi Y; Yasutomi M
Int J Clin Oncol; 2004 Apr; 9(2):98-106. PubMed ID: 15108041
[TBL] [Abstract][Full Text] [Related]
19. Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).
Yoshinaga K; Saeki H; Oki E; Morita M; Ikeda T; Sugimachi K; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Soejima Y; Kawanaka H; Mimori K; Watanabe M; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):549-58. PubMed ID: 24693683
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters.
Ohwada S; Ogawa T; Makita F; Tanahashi Y; Ohya T; Tomizawa N; Satoh Y; Kobayashi I; Izumi M; Takeyoshi I; Hamada K; Minaguchi S; Togo Y; Toshihiko T; Koyama T; Kamio M
Oncol Rep; 2006 Apr; 15(4):861-8. PubMed ID: 16525672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
